Shortage of Sodium Bicarbonate Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Sodium Bicarbonate Injection, affecting multiple manufacturers, with some presentations unavailable due to manufacturing delays or discontinuation.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Sodium Bicarbonate Injection.
What's in Shortage
The generic drug name is Sodium Bicarbonate Injection. Brand names include SODIUM BICARBONATE. The dosage form is Injection. This shortage is listed as current by the FDA, with the initial posting date of 03/01/2017 and last updated on 03/27/2026. It falls under the therapeutic categories of Endocrinology/Metabolism, Gastroenterology, and Pediatric.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: Unavailable for several presentations, including Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02), with next delivery in April 2026 and estimated recovery in June 2026 due to manufacturing delay; Unavailable for Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14) due to discontinuation; Unavailable for Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14) due to discontinuation; Unavailable for Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14) due to discontinuation; Unavailable for Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35), with next delivery and estimated recovery in June 2026 due to manufacturing delay; Unavailable for Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14) due to discontinuation; Unavailable for Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01), with next delivery and estimated recovery in September 2026 due to manufacturing delay. Contact info: 844-646-4398. Also, Available for Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14).
- Exela Pharma Sciences, LLC: Available for Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4); Available for Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5); Available for Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4). Contact info: 828-758-5474 ext. 154.
- Fresenius Kabi USA, LLC: Unavailable for Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05), with next release in April 2026; Available for Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50), check wholesalers for inventory. Contact info: 888-386-1300.
- Amphastar Pharmaceuticals, Inc.: Available for Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1). Contact info: 800-423-4136.
Why There's a Shortage
The general reason for the shortage is listed as 'Other'. Specific manufacturers have noted reasons such as manufacturing delays or discontinuation of certain presentations.
What Patients Should Do
Patients who rely on Sodium Bicarbonate Injection should speak with their pharmacist to check availability and discuss options. They may also contact the relevant manufacturer for more information. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (3,038 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.